SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is rallying on community excitement around imminent EU approval for its cancer therapeutic, Anktiva, and intensified discussions of an 'Immunotherapy 2.0' partnership with Saudi Arabia for broad cancer indications. Investors are anticipating a significant short squeeze, validating the company's undervalued platform against recent industry acquisitions and its mission to deliver 'unstoppable' cancer treatments.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing intense discussion after halting its compounded GLP-1 weight loss pill amid a patent infringement lawsuit from Novo Nordisk and increased FDA scrutiny, creating a sharp divide among investors debating a potential short squeeze against fundamental concerns over regulatory and legal risks.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing intense scrutiny and high volatility after a clinical hold was placed on its gene therapies, RGX-111 and RGX-121, due to a patient developing a brain tumor, leading to widespread community speculation about an impending Complete Response Letter for RGX-121's imminent PDUFA decision.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending due to strong preliminary financial results and significantly raised growth outlook, driven by robust demand for its AI data center connectivity solutions from major hyperscalers. The community is actively discussing its valuation and the ongoing relevance of its copper-based technology amidst recent market volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending sharply lower following the abrupt departures of its CFO and General Counsel amid an accounting review and delayed financial filings, sparking intense community discussion about whether the significant sell-off is an extreme overreaction or indicative of severe internal control issues.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as recent weak guidance for the coming quarter has driven a sell-off and ignited community debate over decelerating automotive and industrial demand. While bears foresee further drops, bulls are underscoring the company's strategic pivot to AI data centers with a significant Nvidia partnership and a large share repurchase program.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is experiencing strong bullish momentum driven by significant analyst upgrades and a new widebody aircraft order from Delta Air Lines. The community is eagerly anticipating robust upcoming earnings, with discussion focused on potential dividend increases, substantial share buybacks, and accelerating prospects in its small modular reactor (SMR) business for AI data centers and ongoing defense sector expansion.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is gaining significant attention for its central role in advanced semiconductor packaging, which is vital for the booming AI sector and enhanced by strategic collaborations with industry leaders like Apple, Nvidia, and TSMC. The community views the company as a key beneficiary of the U.S. manufacturing reshoring trend, anticipating substantial long-term growth as it expands its domestic capabilities.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

monday.com is experiencing a sharp decline after issuing weaker-than-expected guidance and withdrawing long-term targets, intensifying market fears that AI could disrupt its traditional software business model. The community is sharply divided, with some viewing the brutal sell-off as an overreaction given the company's strong cash position and enterprise growth, while others believe AI tools pose a significant threat to the SaaS sector.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following its strong earnings beat, raised guidance, and a new share repurchase program, which are driving renewed bullish sentiment and analyst upgrades. Community discussion centers on its perceived undervaluation and potential for a short squeeze, as the company emphasizes strategic AI innovations within the evolving gig economy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Hold" from Analysts

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One...

Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Hold" by Analysts

Shares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have been assigned an average recommendation of "Hold" from the five brokerages that are currently covering the firm, MarketBeat Ratings...

Insider Buying: Annovis Bio (NYSE:ANVS) Director Buys 45,000 Shares of Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman bought 45,000 shares of the business's stock in a transaction dated Monday, December 8th. The stock was bought at an average...

Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman purchased 45,000 shares of the business's stock in a transaction dated Monday, December 8th. The shares were purchased at an...

Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Hold" from Brokerages

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) has earned a consensus recommendation of "Hold" from the five research firms that are covering the stock, MarketBeat reports. One investment analyst...

Michael Hoffman Acquires 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman purchased 39,200 shares of Annovis Bio stock in a transaction dated Monday, November 24th. The stock was bought at an average...

Michael Hoffman Buys 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman bought 39,200 shares of the company's stock in a transaction that occurred on Monday, November 24th. The shares were bought at...

Annovis Bio (NYSE:ANVS) Director Michael Hoffman Purchases 20,000 Shares

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman purchased 20,000 shares of the business's stock in a transaction dated Friday, November 21st. The stock was bought at an...

Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 15,000 Shares of Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman acquired 15,000 shares of Annovis Bio stock in a transaction dated Friday, November 14th. The shares were bought at an average...

Best Penny Stocks To Watch Now - November 17th

Leap Therapeutics, Autonomix Medical, Cypherpunk Technologies, Annovis Bio, and Datavault AI are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are...

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Annovis Bio Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$2.49
Prev Close	$2.49
Open	$2.56
Dividend Yield	0.00%
50-Day Moving Average	$3.60
Beta	1.53
Avg. Volume	553,419.15
PE Ratio	-1.68

52-Week High	$5.50
52-Week Low	$1.11
Market Capitalization	$65.99M
EPS (Annual)	-$2.31
Price to Book	3.82
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ANVS
Annovis Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANVS News

ANVSAnnovis Bio Inc